Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648 (2023).

Article  CAS  PubMed  Google Scholar 

Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423–431 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manfredi, F. et al. TCR redirected T cells for cancer treatment: achievements, hurdles, and goals. Front. Immunol. 11, 1689 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porter, D. L., Kalos, M., Zheng, Z., Levine, B. & June, C. Chimeric antigen receptor therapy for B-cell malignancies. J. Cancer 2, 331–332 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).

Article  CAS  PubMed  Google Scholar 

Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).

Article  CAS  PubMed  Google Scholar 

Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).

Article  CAS  PubMed  Google Scholar 

Hirayama, A. V. et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 134, 636–640 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+ : CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).

Article  CAS  PubMed  Google Scholar 

Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).

Article  PubMed  Google Scholar 

Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335–347 (2023).

Article  CAS  PubMed  Google Scholar 

Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219–2230 (2024).

Article  CAS  PubMed  Google Scholar 

Healey, N. Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy. Nat. Med. 30, 1795–1796 (2024).

Article  CAS  PubMed  Google Scholar 

Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656–2666 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460–1471 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schober, K. et al. Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nat. Biomed. Eng. 3, 974–984 (2019).

Article  PubMed  Google Scholar 

Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggiero, E. et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci. Transl. Med. 14, eabg8027 (2022).

Article  CAS  PubMed  Google Scholar 

Mastaglio, S. et al. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood 130, 606–618 (2017).

Article  CAS  PubMed  Google Scholar 

Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci. Adv. 9, eadf3700 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat. Rev. Drug. Discov. 22, 976–995 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidts, A. & Maus, M. V. Making CAR T cells a solid option for solid tumors. Front. Immunol. 9, 2593 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Umut, Ö, Gottschlich, A., Endres, S. & Kobold, S. CAR T cell therapy in solid tumors: a short review. Memo 14, 143–149 (2021).

A